These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9862629)

  • 1. Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
    Kizaki M; Muto A; Kinjo K; Ueno H; Ikeda Y
    J Natl Cancer Inst; 1998 Dec; 90(24):1906-7. PubMed ID: 9862629
    [No Abstract]   [Full Text] [Related]  

  • 2. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
    Matsui W; Smith BD; Vala M; Beal N; Huff CA; Diehl LF; Jones RJ
    Br J Haematol; 2005 Mar; 128(6):853-62. PubMed ID: 15755292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
    Fung TK; So CW
    Oncotarget; 2013 Aug; 4(8):1128-9. PubMed ID: 23934744
    [No Abstract]   [Full Text] [Related]  

  • 6. [In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
    Cai X; Jia P; Shi X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):339-41. PubMed ID: 11189513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
    Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
    Huff J; Waalkes M; Nyska A; Chan P
    J Natl Cancer Inst; 1999 Oct; 91(19):1690-1. PubMed ID: 10511603
    [No Abstract]   [Full Text] [Related]  

  • 10. Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
    Wang HX; Duan LN; Ji SQ; Guo ZK
    Leuk Lymphoma; 2006 Jul; 47(7):1438-40. PubMed ID: 16923589
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cell differentiation and apoptosis of tumor cells].
    Zhang T
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1999 May; 19(5):261-2. PubMed ID: 11783236
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Tamm I
    Haematologica; 2005 Dec; 90(12):1585A. PubMed ID: 16330421
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D; Mistry AR; Solomon E; Guidez F
    Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in the study on antineoplastic action of realgar].
    Pan B; Xu L; Yang X
    Zhong Yao Cai; 2004 Mar; 27(3):226-9. PubMed ID: 15346589
    [No Abstract]   [Full Text] [Related]  

  • 15. Arsenic trioxide.
    Wilkinson K
    Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
    [No Abstract]   [Full Text] [Related]  

  • 16. [In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells].
    Zhu Q; Yu Y; Jia PM; Cai X; Chen SJ; Chen Z; Wang ZY; Tong JH
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):6-9. PubMed ID: 12679001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells.
    Ohsawa M; Koyama T; Shibakura M; Kamei S; Hirosawa S
    Leukemia; 2000 May; 14(5):941-3. PubMed ID: 10803529
    [No Abstract]   [Full Text] [Related]  

  • 19. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
    Herst PM; Hesketh EL; Ritchie DS; Berridge MV
    Leuk Res; 2008 Feb; 32(2):327-33. PubMed ID: 17580091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Look AT
    J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.